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A perivascular origin  
for mesenchymal stem cells
Mesenchymal stem cells (MSCs) were initially described in 
the bone marrow, but recent work located them in many adult 
organs, including the kidney. Their most defining characteristic 
is that when expanded in vitro, they can be induced to differen-
tiate into adipogenic, myogenic, chondrogenic, and osteogenic 
lineages, but their function(s) in vivo remains poorly defined. 
Pericytes, or mural cells, also called mesangial cells in the kid-
ney and Ito cells in the liver, closely encircle endothelial cells 
in capillaries and microvessels, where they can inhibit division 
of endothelial cells. Some pericytes contain α-smooth muscle 
actin and regulate microvessel contractility and capillary per-
meability. Pericytes are believed to include progenitors of differ-
ent cell types; it was recently found that pericytes isolated from 
human skeletal muscle can regenerate skeletal myofibers in dys-
trophic immunodeficient mice. To further explore the presence 
of multilineage progenitors among human perivascular cells, 
Crisan et al. first defined a combination of markers that charac-
terizes these cells: CD146, NG2, and PDGF-Rβ expression and 
absence of hematopoietic, endothelial, and myogenic cell mark-
ers (Figure 1). Next, when they isolated perivascular cells from 
skeletal muscles, the pancreas, adipose tissue, and other organs, 
they found that pericytes were myogenic in vivo and ex vivo. 
Irrespective of their tissue origin, long-term cultured perivascu-
lar cells retained myogenicity and exhibited, at the clonal level, 
osteo genic, chondrogenic, and adipogenic potentials. Remark-
ably, pericytes expressed MSC markers and, like these cells, 
migrated in a culture model of chemotaxis. Further, expression 
of MSC markers (CD44, CD73, CD90, and CD105) was also 
detected at the surface of native, non-cultured perivascular cells 
(Figure 2). These interesting results indicate that blood vessel 
walls harbor a reserve of progenitor cells that may be integral 
to the origin of the elusive MSCs and other related adult stem 
cells. Moreover, perivascular cells sorted from diverse tissues and 
cultured over the long term give rise to adherent, multilineage 
progenitor cells that exhibit the features of MSCs. (Cell Stem Cell 
2008; 3: 301–313; doi:10.1016/j.stem.2008.07.003)
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Sodium bicarbonate versus sodium 
chloride to prevent contrast 
medium–induced nephropathy in 
coronary angiography patients
Strategies have been tested to prevent acute kidney injury caused 
by contrast medium, including acetylcysteine, fenoldopam, diu-
retics, intravenous crystalloid solutions, prophylactic hemofiltra-
tion, and, most recently, intravenous bicarbonate. Unfortunately, 
studies testing each of these strategies have provided conflicting 
conclusions. Now, a randomized controlled trial compares the 
effects of intravenous sodium chloride and sodium bicarbonate 
on the outcome of contrast nephrotoxicity.1 Inclusion criteria 
were an estimated glomerular filtration rate of 60 ml/min or less 
and one additional feature from among a history of diabetes mel-
litus, congestive heart failure, or hypertension, or age greater than 
75 years. Subjects received 3 ml/kg of the solution to which they 
were randomized for 1 hour before coronary angiography. The 
rate was decreased to 1.5 ml/kg/h during the procedure and con-
tinued for 4 hours after completion of the procedure. Brar et al.1 
found no difference between treatment groups in the primary end 
point of a 25% or greater decrease in estimated glomerular filtra-
tion rate during days 1–4 after contrast exposure. Of the group 
receiving sodium bicarbonate, 13.3% experienced the primary 
end point. Among the group receiving sodium chloride, 14.6% 
experienced the end point. No difference was found between 
treatment groups for other end points, include death, dialysis, 
myocardial infarction, and cerebro vascular event at 30 days.
These findings contradict a recent study wherein a 
significantly lesser risk was seen among patients who received 
sodium bicarbonate.2 Although these two studies appear to be 
contradictory, Merten et al.2 defined nephrotoxicity as an increase 
in creatinine of 25% within 2 days of contrast exposure, whereas 
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Figure 1 | Immunodetection of perivascular cells in human organs.
Figure 2 | Perivascular cells natively express MSC markers.
Cr
is
an
 e
t a
l./
Ce
ll 
St
em
 C
el
l
1370   Kidney International (2008) 74 
journal  c lub
Brar et al.1 defined the same relative increase within 4 days of 
exposure. Given these differences, a critical threshold of volume 
required to achieve the protective effect could be developed. Also, 
these studies do not disagree on safety. Sodium bicarbonate is 
a well-tolerated therapy with limited downsides to administra-
tion. Its role in the prevention of nephrotoxicity will no doubt 
continue to be defined. (1JAMA 2008; 300: 1038–1046. 2JAMA 
2004; 291: 2328–2334)
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NHERF1 mutations and 
responsiveness of renal 
parathyroid hormone
Impaired renal phosphate reabsorption increases the risks of 
nephrolithiasis and bone demineralization. It is measured by 
division of the tubular maximal reabsorption of phosphate by 
the glomerular filtration rate (TmP/GFR). Data from animal 
models suggest that sodium–hydrogen exchanger regula-
tory factor 1 (NHERF1) controls renal phosphate transport. 
In a new study, Karim et al. sequenced the NHERF1 gene in 
158 patients, 94 of whom had either nephrolithiasis or bone 
demineralization. They identified three distinct mutations in 
seven patients with a low TmP/GFR value. Patients with nor-
mal TmP/GFR values did not have mutations. The mutants 
expressed in cultured renal cells increased the generation 
of cyclic AMP (cAMP) by parathyroid hormone (PTH) and 
inhibited phosphate transport. The mutations were identified 
only in patients with TmP/GFR values that were below nor-
mal and significantly lower than those in patients in whom 
mutations were not identified. In addition, in one family, the 
mutation was associated with a low TmP/GFR value and renal 
stones. These results show that NHERF1 mutations cause renal 
phosphate loss that may increase the risk of renal stone forma-
tion or bone demineralization. Further, these mutations had 
no effect on basal phosphate uptake; instead, they potentiated 
PTH-induced cAMP generation and, as a result, the inhibition 
of phosphate transport. (N Engl J Med 2008; 359: 1128–1135)
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Genetic variants of TNFAIP3  
are associated with  
systemic lupus erythematosus
Systemic lupus erythematosus is an autoimmune disease with 
loss of self-tolerance to cellular antigens. Autoantibody pro-
duction leads to immune complex formation, resulting in 
local and systemic inflammation and organ failure. Although 
the disease is genetically complex, substantial work over the 
past decade has led to the identification of several reproduc-
ible genetic risk factors. The tumor necrosis factor α–induced 
protein 3 (TNFAIP3) gene encodes a ubiquitin editing enzyme, 
A20, which is expressed in multiple cell types and restricts 
NF-κB–dependent signaling. A20 regulates the ubiquitina-
tion of several signaling proteins and restricts the duration of 
both tumor necrosis factor–induced and Toll-like receptor–
induced NF-κB signals. Thus, A20 is a potent endogenous 
anti-inflammatory molecule. Deletion of TNFAIP3 in mice 
leads to severe spontaneous inflammation, cachexia, and pre-
mature death. As TNFAIP3 is well conserved between humans 
and mice and recent evidence linked this gene with rheumatoid 
arthritis, Musone et al. hypothesized that variants in TNFAIP3 
might also be associated with systemic lupus erythematosus 
(SLE).1 To test this, they used data from a recently published 
genome-wide association study and included in the analysis 
1239 cases of SLE and 1629 controls. They found that three 
independent single-nucleotide polymorphisms (SNPs) in the 
TNFAIP3 region are associated with SLE among individuals of 
European ancestry. In a related study, to identify genetic vari-
ants contributing to SLE, Graham et al. tested association of 
311,238 successfully genotyped SNPs in 431 unrelated cases of 
the disease and 2155 controls.2 Three regions met a prespecified 
threshold for genome-wide significance: the previously defined 
human leukocyte antigen and IRF5-TNPO3 regions, and a 
previously unreported SLE locus at chromosome 6q23 within 
the TNFAIP3 gene. Thus, these studies identified a previously 
un reported association between variants in the TNFAIP3 region 
and SLE. The results support the presence of genetic effects that 
are both shared and distinct from the recently described asso-
ciation with rheumatoid arthritis. TNFAIP3, through its role 
as a key regulator of NF-κB signaling, represents a compelling 
candidate locus for further studies of autoimmune patho-
genesis. (1Nat Genet 2008; 40: 1062–1064; doi:10.1038/ng.202. 
2Nat Genet 2008; 40: 1059–1061; doi:10.1038/ng.200)
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Results of sequence analysis of genomic DNA from patients with NHERF1 
mutations.
